These conditions are closely linked to an increased risk of cardiovascular disease, highlighting the importance of effective treatment options
Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial
Abbreviations GLP1-RA: Glucagon like peptide-1 receptor agonist ASCVD: Atherosclerotic cardiovascular disease MACE: Major adverse cardiovascular events NNT: Numbers Needed to Treat MI: Myocardial Infarction CVD: Cardiovascular Disease SGLT2i: Sodium-glucose cotransporter-2 inhibitors LEADER: Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results T2DM: Type 2 Diabetes mellitus SELECT: Semaglutide effects on cardiovascular outcomes in people with overweight or obesity PREVENT: Predicting risk of cardiovascular disease events HF: Heart Failure PRISMA: Preferred reporting items for systematic review and meta-analyses RCT: Randomized controlled trial BMI: Body mass index RR: Risk ratio NNTB: Numbers needed to benefit NNTH: Number needed to harm ROB-2: Cochrane risk of bias 2 (ROB-2) tool FLOW: Evaluate renal function with semaglutide once weekly References Federation WH
While serious interactions are rare, individualized assessment ensures optimal safety, particularly in patients with complex medication regimens or multiple comorbidities common in the population prescribed semaglutide for diabetes or weight management
GLP-1 also limits the release of glucagon, a hormone that raises blood sugar
